Captopril for heart health in Duchenne muscular dystrophy
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a heart medication called captopril in people with Duchenne muscular dystrophy who already have some early heart muscle changes. The goal is to see if it can help protect the heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetic test showing Duchenne muscular dystrophy.
- You must be at least 6 years old.
- Your heart muscle function (GLS) must be below -18%.
- You cannot have kidney problems, low blood pressure, high potassium, or a narrowed heart valve.
- Your heart's pumping strength (ejection fraction) must be 50% or above.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding metoprolol (a beta-blocker) to usual care can prevent or slow cardiomyopathy (heart muscle weakness) in people with Duchenne muscular dystrophy (DMD). It also checks for safety, especially effects on heart rate and rhythm.
This trial tests an experimental therapy for heart weakness caused by Duchenne muscular dystrophy. It aims to improve how heart cells handle calcium to protect heart function.
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
This trial tests if a medicine that improves blood flow, combined with exercise, can help muscles in boys with Duchenne muscular dystrophy. It is for boys who can still walk and are on a stable steroid medication.
This study tests if a type 2 diabetes medicine called empagliflozin can help children who have heart problems caused by Duchenne muscular dystrophy. If you are between 6 and 18 years old and already taking heart failure medications, you may be able to join.
This trial tests whether candesartan (a blood-pressure medicine) can delay or prevent heart muscle weakening in people who carry a disease-causing dilated cardiomyopathy gene variant but still have fairly strong heart pumping. Participants are randomly assigned to candesartan or a placebo to see which one keeps the heart healthier over time.
Hear when a new Effect of Drug trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.